HUME DANIEL 4

What Happened Daniel Hume, a director of TG Therapeutics, was granted 8,325 stock‑tracking units (STUs) on 2026-06-11. The grant is reported as an award/derivative (code A) at a reported price of $0.00; the filing shows no immediate cash paid. These STUs are a contingent right to receive either shares or a cash payment tied to the company’s share fair market value, so there is no immediate share transfer or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15.
• Award: 8,325 STUs granted; reported price $0.00 (derivative award).
• Shares owned after transaction: Not specified in the filing.
• Footnote F1: Each STU may settle for one share or a cash payment equal to one share’s fair market value, at the committee’s discretion, no later than 30 days after the first anniversary of grant.
• Footnote F2: STUs vest on the first anniversary of the grant provided the reporting person remains in continuous service through the vesting date.
• Filing timeliness: Filed 4 days after the transaction date; filing dates are shown on the Form 4 (no late‑filing flag noted in the summary data).

Context This is a compensation award (derivative grant), not an open‑market purchase or sale. The economic value to the insider depends on future vesting and the company’s share price (or a cash settlement) after the one‑year vesting period; therefore it does not represent an immediate buy/sell signal.